SPRUCE BIOSCIENCES INC (SPRB) competitors & alternatives
Health Care · NASDAQ
SPRUCE BIOSCIENCES INC (SPRB)'s top competitors and alternatives — its most similar public companies — include BioMarin Pharmaceutical (BMRN), Ultragenyx (RARE), DENALI THERAPEUTICS INC (DNLI), PTC THERAPEUTICS INC (PTCT), TRAVERE THERAPEUTICS INC (TVTX), Jazz Pharmaceuticals (JAZZ), SOLID BIOSCIENCES INC (SLDB), HARMONY BIOSCIENCES HLDG INC (HRMY), SAVARA INC (SVRA), MIRUM PHARMACEUTICALS INC (MIRM), Alnylam Pharmaceuticals (ALNY) and OMEROS CORP (OMER). These are SPRUCE BIOSCIENCES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SPRB competitors & alternatives
-
BioMarin PharmaceuticalBMRNHealth Care
BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene…
$58.40 (as of 2026-07-22) · market cap $11.3B
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
DENALI THERAPEUTICS INCDNLIHealth Care
Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the…
$23.64 (as of 2026-07-22) · market cap $3.7B
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
-
TRAVERE THERAPEUTICS INCTVTXHealth Care
Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first…
$56.26 (as of 2026-07-22) · market cap $5.2B
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
HARMONY BIOSCIENCES HLDG INCHRMYHealth Care
Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor…
$34.86 (as of 2026-07-22) · market cap $2.0B
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
MIRUM PHARMACEUTICALS INCMIRMHealth Care
Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic…
$114.48 (as of 2026-07-22) · market cap $7.0B
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
OMEROS CORPOMERHealth Care
A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem…
$9.84 (as of 2026-07-22) · market cap $703M
Not quite? Describe exactly what you want →
Peers are SPRUCE BIOSCIENCES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: SPRUCE BIOSCIENCES INC (SPRB).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.